目的 研究西黃丸對Walker256乳腺癌細(xì)胞荷瘤大鼠的抗腫瘤及對相關(guān)炎性因子的調(diào)節(jié)作用，探討其抗腫瘤作用機(jī)制。方法 60只雌性Wistar大鼠，隨機(jī)抽取10只設(shè)為對照組，剩余50只建立荷瘤大鼠模型，隨機(jī)分為模型組、西黃丸高、中、低劑量組和香菇多糖組，每組10只，按10 mL/kg ig給藥，每天2次，連續(xù)14 d。14 d后腹主動脈取血，取瘤組織稱定質(zhì)量，計(jì)算抑瘤率；采用ELISA法檢測大鼠外周血IL-2、IFN-γ、IL-6、IL-10和TGF-β水平。結(jié)果 西黃丸高、中、低劑量組抑瘤率分別為33.1%、30.7%、28.5%；與對照組比較，西黃丸高、中、低劑量均可明顯提高荷瘤大鼠外周血IL-2、IFN-γ的水平，降低IL-6、IL-1、GF-β水平（P＜0.05）。結(jié)論 西黃丸具有明顯的抑制腫瘤生長的作用，可通過提高荷瘤大鼠IL-2、IFN-γ水平增強(qiáng)免疫清除功能；降低IL-6、IL-10、TGF-β水平，減少形成免疫抑制微環(huán)境的相關(guān)炎性因子，呈現(xiàn)出逆轉(zhuǎn)腫瘤免疫逃逸的趨勢。

Objective To study the antitumor activity of Xihuang Pill on the growth of Walker 256 breast cancer cell in tumer-bearing rats and the regulatory role of the inflammatory cytokines of Xihuang Pill, and to explore its antitumor mechanism. Methods Ten of 60 female Wistar rats were seemed as control group and the remained 50 rats were established as tumor-bearing rat models which were randomly divided into five groups (each group with ten rats): model group, high-, mid-dose, and low-dose Xihuang Pill, and lentinan groups. Each group was treatedt by ig administration twice daily for 14 d. After 14 d, the tumor was removed and weighed to calculate inhibitory rate. The levels of IL-2, IFN-γ, IL-6, IL-10 and TGF-β in peripheral blood were determined by ELISA. Results The tumor-inhibitory rates of high-, mid-, and low-dose Xihuang Pill groups were 33.1%, 30.7%, and 28.5%. Compared with the control group, the average levels of IL-2 and IFN-γ of the high-, mid-, and low-dose Xihuang Pill groups increased, and the levels of IL-6, IL-10 and TGF-β decreased (P < 0.05). Conclusion Xihuang Pill has an obvious antitumor action which can enhance the expression of IL-2 and IFN-γ and reduce the expression of IL-6, IL-10, and TGF-β. The increase of the levels of IL-2 and IFN-γ could improve the immune clearance function and the decline of the levels of IL-6, IL-10 and TGF-β could reduce the expression of the related inflammatory factors in the immunosuppressive microenvironment which shows a trend to reverse tumor immune escape.